PB 101 - PlateletBio
Alternative Names: PB-101 - PlateletBioLatest Information Update: 11 Feb 2022
At a glance
- Originator PlateletBio
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Idiopathic thrombocytopenic purpura
Most Recent Events
- 11 Feb 2022 PlateletBio announces intention to submit IND for Immune thrombocytopenia in the first half of 2022 (PlateletBio pipeline, February 2022)
- 05 Nov 2021 PlateletBio announces intention to submit IND application for Idiopathic thrombocytopenic purpura
- 05 Nov 2021 PlateletBio plans a clinical trial for Idiopathic thrombocytopenic purpura (Parenteral)